Concomitant use w/ CYP2C9 isoenzyme inhibitors may alter safety and efficacy of mefenamic acid. May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events w/ aspirin. May reduce the natriuretic effects of furosemide or thiazide diuretics. Reduced renal lithium clearance and elevated plasma lithium levels. May enhance anticoagulant effect of warfarin.
Each tablet contains 500 mg of mefenamic acid.
The Journey of Watsons Own Brand products
With our commitment to Quality Assurance, our products go through quality assessments throughout the production journey which lasts up to 18 months.